2023-09-12 08:32:56 ET
More on DiaMedica Therapeutics
- Seeking Alpha’s Quant Rating on DiaMedica Therapeutics
- Historical earnings data for DiaMedica Therapeutics
- Financial information for DiaMedica Therapeutics
- DiaMedica Therapeutics Inc. ( DMAC ) Q2 2023 Earnings Call Transcript
- DiaMedica Therapeutics: Risk-Reward Favors Following Insider Optimism
- DiaMedica Therapeutics GAAP EPS of -$0.16 beats by $0.02
- DiaMedica Therapeutics up ~5%, reports directors and execs buying stock
- FDA lifts clinical hold on DiaMedica's Phase 2/3 study for stroke drug
For further details see:
DiaMedica appoints Ambarish Shah, Ph.D. as CTO